References
- Berthelot P, Dhumeaux D. (1978). New insights into the classification and mechanisms of hereditary, chronic, non-hemolytic hyperbilirubinaemias. Gut 19:474–80
- Campbell SD, Lau WF, Xu JJ. (2009). Interaction of porphyrins with human organic anion transporting polypeptide 1B1. Chem Biol Interact 182:45–51
- Capelle P, Dhumeaux D, Mora M, et al. (1972). Effect of rifampicin on liver function in man. Gut 13:366–71
- Fromm MF. (2012). Prediction of transporter mediated drug–drug interactions using endogenous compounds. Clin Pharmacol Ther 92:546–8
- Giacomini KM, Huang SM, Tweedie DJ, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–36
- Ho RH, Kim RB. (2005). Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78:260–77
- Ho RH, Tirona RG, Leake BF, et al. (2006). Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793–806
- Jirsa M, Knisely AS, Schinkel A, Kmoch S. (2012). Rotor syndrome. In: Pagon RA, Adam MP, Bird TD, et al., eds. GeneReviews. Seattle: University of Washington, 1993–2013
- Keppler D. (2014). The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugate hyperbilirubinemia. Drug Metab Dispos 42:561–5
- Li XL, Guo ZT, Wang YD, et al. (2015). Potential role of organic anion transporting polypeptide 1B1 (OATP1B1). in the selective hepatic uptake of hematoporphyrin monomethyl ether isomers. Acta Pharmacol Sin 36:268–80
- Matthews JN, Altman DG, Campbell MJ, Royston P. (1990). Analysis of serial measurements in medical research. Br Med J 300:230–5
- Niemi M, Pasanen MK, Neuvonen PJ. (2011). Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157–81
- Prasad B, Evers R, Gupta A, et al. (2013). Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1). Protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab Dispos 42:78–88
- Schuetz JD, Swaan PW, Tweedie DJ. (2014). The role of transporters in toxicity and disease. Drug Metab Dispos 42:541–5
- Servais A, Lechat P, Zahr N, et al. (2006). Tubular transporters and clearance of adefovir. Eur J Pharmacol 540:168–74
- Shimizu Y, Ida S, Naruto H, Urata G. (1978). Excretion of porphyrins in urine and bile after the administration of delta-aminolevulinic acid. J Lab Clin Med 92:795–802
- Shimizu Y, Naruto H, Ida S, Kohakura M. (1981). Urinary coproporphyrin isomers in Rotor's syndrome: a study in eight families. Hepatology 1:173–8
- Vildhede A, Karlgren M, Svedberg EK, et al. (2014). Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions. Drug Metab Dispos 42:1210–18
- van de Steeg E, Wagenaar E, van der Kruijssen CM, et al. (2010). Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest 120:2942–52
- van de Steeg E, Stránecký V, Hartmannová H, et al. (2012). Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 122:519–28
- Ulrich DL, Lynch J, Wang Y, et al. (2012). ATP-dependent mitochondrial porphyrin importer ABCB6 protects against phenylhydrazine toxicity. J Biol Chem 287:12679–90
- Wolkoff AW, Wolpert E, Pascasio FN, Arias IM. (1976). Rotor's syndrome. A distinct inheritable pathophysiologic entity. Am J Med 60:173–9
- Zimniak P. (1993). Dubin–Johnson and Rotor syndromes: molecular basis and pathogenesis. Semin Liver Dis 13:248–60